Shares of Eli Lilly plunged Monday after the drugmaker said it would stop developing a heart disease treatment that had advanced deep into clinical testing. The Indianapolis company said researchers cited a lack of effectiveness, not safety concerns, in recommending an end to late-stage research on the drug, evacetrapib.
Are you up for a challenge?
